Therapeutics News and Research

RSS

Pulmokine receives NIH SBIR grants to develop novel treatments for PAH

YM BioSciences Inc., today reported that Pulmokine Inc. (Slingerlands, New York), a licensee of several small molecule compounds from YM, has been awarded two National Institutes of Health (NIH) Small Business Innovation Research (SBIR) grants. The grants, totaling more than US$650,000, are Phase I awards to develop novel treatments for Pulmonary Arterial Hypertension (PAH).

29 Sep 2010

Cedars-Sinai physicians to lead St. Jude Medical's transcatheter aortic valve implantation clinical trial

St. Jude Medical, Inc., a global medical device company, today announced that physicians from the Cedars-Sinai Heart Institute will lead the company's transcatheter aortic valve implantation (TAVI) clinical trial. The study will evaluate the safety and efficacy of the St. Jude Medical transcatheter aortic valve for patients who experience severe aortic stenosis and who may be at an elevated risk for open-heart surgery.

29 Sep 2010

Crescendo Biologics successfully delivers triple knockout mice

Crescendo Biologics Limited today announces it has established a colony of engineered mice completely devoid of endogenous antibody polypeptides. The proprietary 'triple knockout' mice are believed to be unique and have the immunoglobulin heavy chain (IgH), kappa light chain and lambda light chain loci all functionally silenced by large-scale genomic deletion.

29 Sep 2010

BAC completes feasibility study on CaptureSelect affinity ligands for Genmab

BAC BV, the leading provider of antibody-based affinity purification technology, today announced that it successfully completed a feasibility study in its collaboration with Genmab A/S (Copenhagen, Denmark), an international biotechnology company developing human antibody therapeutics for the potential treatment of cancer.

29 Sep 2010

Synosia's SYN-118 HPPD inhibitor beneficial for Parkinson's patients: Study

Synosia Therapeutics today announced the first clinical study results showing that SYN-118 provides clinically meaningful benefits to Parkinson's patients, has a good safety profile and is well tolerated. Results from an open-label, proof-of-mechanism study of SYN-118 (CL02) were presented at the World Parkinson Congress in Glasgow, Scotland.

29 Sep 2010

Ready-to-Use Cardene I.V. lowers acutely elevated blood pressure: CLUE study

Results from the CLUE study, a head-to-head comparison between Ready-to-Use Cardene I.V. (nicardipine) and labetalol in the emergency room, showed that Ready-to-Use Cardene I.V. lowers acutely elevated blood pressure more effectively than labetalol. These data were presented today at the annual meeting of the American College of Emergency Physicians (ACEP) in Las Vegas, Nevada.

29 Sep 2010

KINAXO, Daiichi Sankyo enter long-term partnership in cancer research

KINAXO Biotechnologies GmbH and Daiichi Sankyo Company Limited entered a long-term partnership in cancer research. Under the agreement, Daiichi Sankyo will employ KINAXO's technology platform to support the development of Daiichi Sankyo's targeted cancer drugs.

29 Sep 2010

Critical piece of puzzle in treatment of Spinal Muscular Atrophy

University of Missouri researchers believe they have found a critical piece of the puzzle for the treatment of Spinal Muscular Atrophy (SMA) - the leading genetic cause of infantile death in the world. Nearly one in 6,000 births has SMA, and it is estimated that nearly one in 30 to 40 people have the trait that leads to SMA.

29 Sep 2010

Pieris enters multi-year collaboration with Sanofi-Aventis and Sanofi Pasteur for Anticalin technology

Pieris AG announced today the signature of a collaboration and license agreement with both Sanofi-Aventis and Sanofi Pasteur, the vaccines division of the sanofi-aventis Group, under which Pieris will apply its proprietary Anticalin technology to discover novel Anticalin drugs against multiple targets, with further development undertaken by Sanofi-Aventis and Sanofi-Pasteur. The collaboration will initially involve two targets nominated by Sanofi-Aventis and Sanofi-Pasteur, and includes the option for four additional targets.

29 Sep 2010

NCI awards A&G $1.2M Phase II SBIR grant for development of breast cancer drug candidate

A&G Pharmaceutical announced today that it has received $1.2 million in Phase II Small Business Innovation Research (SBIR) funding from the National Cancer Institute (NCI) for the program, "Novel Targeted Therapy for Breast Cancer," focused on the development of a neutralizing therapeutic antibody against a novel cancer-associated protein, GP88.

29 Sep 2010

Chelsea Therapeutics announces $35 million in shares in registered public offering

Chelsea Therapeutics International, Ltd. announced today its intention, subject to market and other conditions, to offer $35 million in shares of its common stock in a registered public offering pursuant to its existing shelf registration statement.

29 Sep 2010

Onconova Therapeutics to present Ex-RAD radioprotectant data at RRS Annual Meeting

Onconova Therapeutics, Inc. is presenting new data in five posters and an oral presentation this week summarizing several studies with the company's radioprotectant Ex-RAD- at the 56th Annual Meeting of the Radiation Research Society (RRS), September 25-29 in Maui, Hawaii.

28 Sep 2010

DecImmune Therapeutics receives funds to improve ischemia reperfusion injury outcomes

DecImmune Therapeutics announced today that it has received a $1 million equity investment from Astellas Venture Management and has additionally been awarded $2.2 million in Phase II SBIR funding from the National Institutes of Health.

28 Sep 2010

Guided Therapeutics files PMA for LightTouch Cervical Scanner

Guided Therapeutics, Inc. announced that it filed its completed premarket approval application (PMA) for the LightTouch Cervical Scanner with the U.S. Food and Drug Administration (FDA) for patients at risk for cervical cancer.

28 Sep 2010

UGA researcher receives NIH award for high-risk, high-reward carbohydrate research

The National Institutes of Health has awarded a prestigious EUREKA award to Robert Woods, a professor at the University of Georgia Complex Carbohydrate Research Center, to develop a new method for understanding how antibodies interact with large molecules known as glycans that are a major component of all cell surfaces.

27 Sep 2010

Chelsea Therapeutics initiates CH-4051 Phase II trial in rheumatoid arthritis patients

Chelsea Therapeutics International, Ltd. has initiated enrollment in a multinational, 12-week, double-blind Phase II trial designed to compare the efficacy and tolerability of CH-4051 against methotrexate (MTX) in 250 patients with rheumatoid arthritis (RA) who are experiencing an inadequate response to MTX treatment.

27 Sep 2010

Early recipient of transcatheter aortic valve receives Courageous Patient Award

Lillian Feldshuh, of Scarsdale, NY, an early recipient of a transcatheter aortic valve in 2006, received the Courageous Patient Award yesterday at the Transcatheter Cardiovascular Therapeutics scientific symposium in Washington, DC. The procedure was a success and Feldshuh, who will turn 100 years in just 7 months, remains in good health.

27 Sep 2010

Clinical trial results of Genous Bio-engineered R stent, EPC capture technology presented at TCT 2010

OrbusNeich today announced that clinical trial results highlighting the company's Genous Bio-engineered R stent and its endothelial progenitor cell capture technology across challenging patient subsets were presented during a symposium titled "EPC Capture Technology: from Genous to Combo" at Transcatheter Cardiovascular Therapeutics 2010 in Washington.

27 Sep 2010

Progenika receives CE Mark approval to market LPLchip in Europe

Progenika Biopharma S.A., a pioneer in the field of personalized medicine, announced today that it has obtained the CE Mark allowing the sale in Europe of its LPLchip(R), the first DNA chip to detect mutations in the lipoprotein lipase (LPL) gene.

27 Sep 2010

Boston releases HORIZONS-AMI trial data

Angiotech Pharmaceuticals, Inc. announced that its corporate partner, Boston Scientific Corporation, has released three-year follow-up data from the HORIZONS-AMI trial.

27 Sep 2010

Therapeutics News and Research

Pulmokine receives NIH SBIR grants to develop novel treatments for PAH

Cedars-Sinai physicians to lead St. Jude Medical's transcatheter aortic valve implantation clinical trial

Crescendo Biologics successfully delivers triple knockout mice

BAC completes feasibility study on CaptureSelect affinity ligands for Genmab

Synosia's SYN-118 HPPD inhibitor beneficial for Parkinson's patients: Study

Ready-to-Use Cardene I.V. lowers acutely elevated blood pressure: CLUE study

KINAXO, Daiichi Sankyo enter long-term partnership in cancer research

Critical piece of puzzle in treatment of Spinal Muscular Atrophy

Pieris enters multi-year collaboration with Sanofi-Aventis and Sanofi Pasteur for Anticalin technology

NCI awards A&G $1.2M Phase II SBIR grant for development of breast cancer drug candidate

Chelsea Therapeutics announces $35 million in shares in registered public offering

Onconova Therapeutics to present Ex-RAD radioprotectant data at RRS Annual Meeting

DecImmune Therapeutics receives funds to improve ischemia reperfusion injury outcomes

Guided Therapeutics files PMA for LightTouch Cervical Scanner

UGA researcher receives NIH award for high-risk, high-reward carbohydrate research

Chelsea Therapeutics initiates CH-4051 Phase II trial in rheumatoid arthritis patients

Early recipient of transcatheter aortic valve receives Courageous Patient Award

Clinical trial results of Genous Bio-engineered R stent, EPC capture technology presented at TCT 2010

Progenika receives CE Mark approval to market LPLchip in Europe

Boston releases HORIZONS-AMI trial data

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News